Core Viewpoint - A securities fraud class action lawsuit has been filed against Lantheus Holdings, Inc. for misrepresentations regarding its key product, Pylarify, affecting investors who acquired securities between February 26, 2025, and August 5, 2025 [1][4][3] Group 1 - The lawsuit was initiated in the United States District Court for the Southern District of New York [3] - Investors are reminded of a deadline to file as lead plaintiff by November 10, 2025, with no fees or expenses required from shareholders [5] - Bernstein Liebhard LLP has a history of recovering over $3.5 billion for clients and has been recognized for its litigation success [6]

NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Avantor, Inc. (“Avantor” or the “Company”) (NYSE: AVTR) between March 5, 2024 and October 28, 2025, inclusive. For more information, submit a form at Avantor, Inc. Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@bernlieb.com, or call us at (212 ...

Core Viewpoint - A securities fraud class action lawsuit has been filed against James Hardie Industries plc, alleging misrepresentation regarding the strength of its North America Fiber Cement segment during a challenging market period [4][5]. Group 1: Lawsuit Details - The lawsuit was initiated in the United States District Court for the Northern District of Illinois on behalf of investors who purchased or acquired James Hardie common stock between May 20, 2025, and August 18, 2025 [4]. - The allegations include violations of the Securities Exchange Act of 1934 against the Company and certain senior officers [4]. Group 2: Investor Participation - Investors wishing to serve as lead plaintiff must file necessary documents by December 23, 2025, with the option to remain an absent class member if no action is taken [6]. - All representation in the lawsuit is on a contingency fee basis, meaning shareholders incur no fees or expenses [6]. Group 3: Law Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented large public and private pension funds [7]. - The firm has been recognized multiple times in The National Law Journal's "Plaintiffs' Hot List" and has been listed in The Legal 500 for sixteen consecutive years [7].

Core Points - A securities fraud class action lawsuit has been filed against MoonLake Immunotherapeutics, alleging violations of the Securities Exchange Act of 1934 [3][4] - The lawsuit claims that the company made misrepresentations regarding its drug candidate, sonelokimab (SLK), which was marketed as superior to competing monoclonal antibody drugs [4] Summary by Sections Lawsuit Details - The lawsuit was initiated on behalf of investors who purchased or acquired MoonLake common stock between March 10, 2024, and September 29, 2025 [3] - Investors are reminded of a deadline to file as lead plaintiff by December 15, 2025, with no fees or expenses required from shareholders [5] Company Background - Bernstein Liebhard LLP, the law firm handling the case, has recovered over $3.5 billion for clients since 1993 and has a strong track record in class action litigation [6]

Core Viewpoint - Baxter International Inc. is facing a securities fraud class action lawsuit due to alleged misrepresentations regarding the safety of its Novum IQ Large Volume Pump, which is claimed to have systemic issues that could endanger patients [3][4]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Northern District of Illinois on behalf of investors who purchased Baxter common stock between February 23, 2022, and July 30, 2025 [3]. - The allegations include violations of the Securities Exchange Act of 1934 against Baxter and certain senior officers [3]. Group 2: Investor Participation - Investors who wish to serve as lead plaintiffs must file papers by December 15, 2025, and can act on behalf of other class members [5]. - Participation as a lead plaintiff is not required to share in any potential recovery, and all representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [5]. Group 3: Law Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented large public and private pension funds [6]. - The firm has been recognized multiple times for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years [6].

Core Viewpoint - WPP plc is facing a securities fraud class action lawsuit alleging misrepresentations regarding its media arm's ability to handle macroeconomic challenges [3] Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Southern District of New York for investors who purchased WPP common stock between February 27, 2025, and July 8, 2025 [3] - Allegations include violations of the Securities Exchange Act of 1934 against WPP and certain senior officers [3] - The lawsuit claims that the defendants misrepresented WPP's media arm's capabilities in the face of ongoing macroeconomic challenges [3] Group 2: Legal Participation - Investors wishing to serve as lead plaintiff must file papers by December 8, 2025 [4] - Serving as lead plaintiff is not required to share in any potential recovery from the lawsuit [4] - All legal representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [4] Group 3: Law Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented large public and private pension funds [5] - The firm has been recognized in The National Law Journal's "Plaintiffs' Hot List" thirteen times and has been listed in The Legal 500 for sixteen consecutive years [5]

NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Baxter International Inc. (NYSE: BAX)?Did you purchase your shares between February 23, 2022 and July 30, 2025, inclusive?Did you lose money in your investment in Baxter International Inc.?Do you want to discuss your rights? Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Baxter International Inc. (“Baxter” or the “Company”) (NYSE: BAX) investors of an upcoming deadline invo ...

Core Points - A securities fraud class action lawsuit has been filed against WPP plc, alleging violations of the Securities Exchange Act of 1934 [2] - The lawsuit claims that WPP misrepresented its media arm's capabilities to handle macroeconomic challenges [2] - Investors who purchased WPP common stock between February 27, 2025, and July 8, 2025, are eligible to participate in the lawsuit [2][3] Legal Proceedings - The deadline to file as a lead plaintiff in the class action is December 8, 2025 [3] - Representation in the lawsuit is on a contingency fee basis, meaning shareholders incur no fees or expenses [3] - Investors can remain absent class members if they choose not to take action [3] Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has a strong track record in class action litigation [4] - The firm has been recognized multiple times in The National Law Journal's "Plaintiffs' Hot List" and has been listed in The Legal 500 for sixteen consecutive years [4]

Core Viewpoint - A securities fraud class action lawsuit has been initiated against MoonLake Immunotherapeutics, alleging misrepresentations regarding its drug candidate sonelokimab [3][4]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Southern District of New York on behalf of investors who purchased or acquired MoonLake common stock between March 10, 2024, and September 29, 2025 [3]. - The allegations include violations of the Securities Exchange Act of 1934 against the Company and certain senior officers [3]. Group 2: Company Information - MoonLake's sole drug candidate, sonelokimab, was promoted as superior to competing monoclonal antibody drugs, which is central to the allegations in the lawsuit [4]. - Investors are reminded of a deadline to file as lead plaintiff by December 15, 2025, which allows them to represent the class in the litigation [5]. Group 3: Legal Representation - Bernstein Liebhard LLP, the law firm handling the case, operates on a contingency fee basis, meaning shareholders pay no fees or expenses unless there is a recovery [5][6]. - The firm has a history of recovering over $3.5 billion for clients and has been recognized multiple times for its litigation success [6].

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Baxter International Inc. for misrepresentations regarding the safety of its Novum IQ Large Volume Pump, which allegedly concealed systemic issues that could lead to severe injury and death for patients [1][2]. Group 1: Lawsuit Details - The lawsuit represents investors who purchased Baxter's common stock between February 23, 2022, and July 30, 2025 [1]. - Defendants are accused of misrepresenting the safety of the Novum IQ Large Volume Pump, a device used for intravenous fluid delivery [2]. - The lawsuit highlights that systemic issues were concealed, putting patients at risk [2]. Group 2: Legal Process - Interested parties wishing to serve as lead plaintiff must file papers by December 15, 2025 [3]. - Serving as lead plaintiff allows representation of other class members in directing the litigation, but recovery does not require this role [3]. - All legal representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [3]. Group 3: Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented large public and private pension funds [4]. - The firm has been recognized for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times [4]. - It has also been listed in The Legal 500 for sixteen consecutive years [4].